Relevant bibliographies by topics / Ejection fraction / Journal articles
To see the other types of publications on this topic, follow the link: Ejection fraction.

Journal articles on the topic 'Ejection fraction'

Author: Grafiati
Published: 4 June 2021
Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Ejection fraction.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Konstam, Marvin A., and François M. Abboud. "Ejection Fraction." Circulation 135, no. 8 (February 21, 2017): 717–19. http://dx.doi.org/10.1161/circulationaha.116.025795.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Shah, Dr Reena, Dr Sunita J. Solanki, Dr Prakash patel, and Dr Neeraj Singh Dr.Neeraj Singh. "Study of Incidence of Heart Failure with Reduced Ejection Fraction and Heart Failure with Normal Ejection Fraction." International Journal of Scientific Research 2, no. 10 (June 1, 2012): 1–2. http://dx.doi.org/10.15373/22778179/oct2013/104.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Butler, Javed, Milton Packer, Gerasimos Filippatos, Joao Pedro Ferreira, Cordula Zeller, Janet Schnee, Martina Brueckmann, Stuart J. Pocock, Faiez Zannad, and Stefan D. Anker. "Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction." European Heart Journal 43, no. 5 (December 8, 2021): 416–26. http://dx.doi.org/10.1093/eurheartj/ehab798.

Full text
Abstract:
Abstract Aims No therapy has shown to reduce the risk of hospitalization for heart failure across the entire range of ejection fractions seen in clinical practice. We assessed the influence of ejection fraction on the effect of the sodium–glucose cotransporter 2 inhibitor empagliflozin on heart failure outcomes. Methods and results A pooled analysis was performed on both the EMPEROR-Reduced and EMPEROR-Preserved trials (9718 patients; 4860 empagliflozin and 4858 placebo), and patients were grouped based on ejection fraction: <25% (n = 999), 25–34% (n = 2230), 35–44% (n = 1272), 45–54% (n = 2260), 55–64% (n = 2092), and ≥65% (n = 865). Outcomes assessed included (i) time to first hospitalization for heart failure or cardiovascular mortality, (ii) time to first heart failure hospitalization, (iii) total (first and recurrent) hospitalizations for heart failure, and (iv) health status assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ). The risk of cardiovascular death and hospitalization for heart failure declined progressively as ejection fraction increased from <25% to ≥65%. Empagliflozin reduced the risk of cardiovascular death or heart failure hospitalization, mainly by reducing heart failure hospitalizations. Empagliflozin reduced the risk of heart failure hospitalization by ≈30% in all ejection fraction subgroups, with an attenuated effect in patients with an ejection fraction ≥65%. Hazard ratios and 95% confidence intervals were: ejection fraction <25%: 0.73 (0.55–0.96); ejection fraction 25–34%: 0.63 (0.50–0.78); ejection fraction 35–44%: 0.72 (0.52–0.98); ejection fraction 45–54%: 0.66 (0.50–0.86); ejection fraction 55–64%: 0.70 (0.53–0.92); and ejection fraction ≥65%: 1.05 (0.70–1.58). Other heart failure outcomes and measures, including KCCQ, showed a similar response pattern. Sex did not influence the responses to empagliflozin. Conclusion The magnitude of the effect of empagliflozin on heart failure outcomes was clinically meaningful and similar in patients with ejection fractions <25% to <65%, but was attenuated in patients with an ejection fraction ≥65%. Key Question How does ejection fraction influence the effects of empagliflozin in patients with heart failure and either a reduced or a preserved ejection fraction? Key Finding The magnitude of the effect of empagliflozin on heart failure outcomes and health status was similar in patients with ejection fractions <25% to <65%, but it was attenuated in patients with an ejection fraction ≥65%. Take Home Message The consistency of the response in patients with ejection fractions of <25% to <65% distinguishes the effects of empagliflozin from other drugs that have been evaluated across the full spectrum of ejection fractions in patients with heart failure.
APA, Harvard, Vancouver, ISO, and other styles
4

Robotham, James L., Masao Takata, Michael Berman, and Yasuhiko Harasawa. "Ejection Fraction Revisited." Anesthesiology 74, no. 1 (January 1, 1991): 172–83. http://dx.doi.org/10.1097/00000542-199101000-00026.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

SIEGEL, ALAN, J. CHRISTOPHER KUHN, HARTE CROW, and STEPHEN HOLTZMAN. "Gallbladder Ejection Fraction." Clinical Nuclear Medicine 25, no. 1 (January 2000): 1. http://dx.doi.org/10.1097/00003072-200001000-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kevorkian, C. George, Seema V. Nambiar, and Diana H. Rintala. "Low Ejection Fraction." American Journal of Physical Medicine & Rehabilitation 84, no. 9 (September 2005): 655–61. http://dx.doi.org/10.1097/01.phm.0000176447.18405.50.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Miller, Leslie W. "Cardiac Ejection Fraction." Journal of the American College of Cardiology 72, no. 6 (August 2018): 602–4. http://dx.doi.org/10.1016/j.jacc.2018.06.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

KALLOO, ANTHONY N., SAMUEL SOSTRE, GARY E. MEYERROSE, PANKAJ J. PASRICHA, and ZSOLT SZABO. "Gallbladder Ejection Fraction." Clinical Nuclear Medicine 19, no. 8 (August 1994): 713–19. http://dx.doi.org/10.1097/00003072-199408000-00015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Richmond, Bryan K., and Robert Fanelli. "Gallbladder Ejection Fraction." Journal of the American College of Surgeons 227, no. 2 (August 2018): 295–96. http://dx.doi.org/10.1016/j.jamcollsurg.2018.03.035.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Marmor, Alon, Diwakar Jain, and Barry Zaret. "Beyond ejection fraction." Journal of Nuclear Cardiology 1, no. 5 (September 1994): 477–86. http://dx.doi.org/10.1007/bf02961601.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Kolias, Theodore J., and Thor Edvardsen. "Beyond Ejection Fraction." JACC: Cardiovascular Imaging 9, no. 8 (August 2016): 922–23. http://dx.doi.org/10.1016/j.jcmg.2015.10.029.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Morecroft, J. A., and M. H. Thomas. "Radionuclide ejection fraction." British Journal of Surgery 75, no. 2 (February 1988): 188. http://dx.doi.org/10.1002/bjs.1800750239.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Pardy, B. J. "Radionuclide ejection fraction." British Journal of Surgery 75, no. 5 (May 1988): 498. http://dx.doi.org/10.1002/bjs.1800750540.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Black, David E., Jen Bryant, Charles Peebles, Keith M. Godfrey, Mark Hanson, and Joseph J. Vettukattil. "Tissue motion annular displacement of the mitral valve using two-dimensional speckle tracking echocardiography predicts the left ventricular ejection fraction in normal children." Cardiology in the Young 24, no. 4 (June 27, 2013): 640–48. http://dx.doi.org/10.1017/s1047951113000863.

Full text
Abstract:
AbstractBackground: The gold standard for determining the left ventricular ejection fraction is cardiac magnetic resonance imaging. Other parameters for determining the ejection fraction such as M-mode echocardiography are operator-dependant and often inaccurate. Assessment of the displacement of the mitral valve annulus using two-dimensional speckle tracking echocardiography may provide an accurate and simple method of determining the left ventricular ejection fraction in children. Method: We retrospectively studied 70 healthy 9-year-old children with no history of cardiovascular disease who had been assessed using cardiac magnetic resonance imaging and two-dimensional transthoracic echocardiography. Mitral displacement was determined using the tissue motion annular displacement (TMAD) feature of Philips QLAB version 9. The midpoint displacement of the mitral valve was calculated, and the predicted left ventricular ejection fraction was compared with magnetic resonance imaging-derived and M-mode-derived ejection fractions. Results: The mean ejection fraction derived from magnetic resonance imaging (64.5 (4.6)) was similar to that derived from the TMAD midpoint (60.9 (2.7), p = 0.001) and the M-mode (61.9 (7), p = 0.012). The TMAD midpoint correlated strongly with the magnetic resonance imaging-derived ejection fraction (r = 0.69, p < 0.001), as did the predicted fraction (r = 0.67, p < 0.001). The M-mode ejection fraction showed a poor linear correlation with both magnetic resonance imaging-derived and TMAD-derived fractions (r = 0.33 and 0.04, respectively). Conclusion: TMAD of the mitral valve is a simple, effective, and highly reproducible method of assessing the ejection fraction in normal children. It shows a strong linear correlation with magnetic resonance imaging-derived ejection fraction and is superior to M-mode-derived ejection fractions.
APA, Harvard, Vancouver, ISO, and other styles
15

Shoucri, Rachad M. "Ejection Fraction and ESPVR." International Heart Journal 54, no. 5 (2013): 318–27. http://dx.doi.org/10.1536/ihj.54.318.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Fonarow, Gregg C., and Jeffrey J. Hsu. "Left Ventricular Ejection Fraction." JACC: Heart Failure 4, no. 6 (June 2016): 511–13. http://dx.doi.org/10.1016/j.jchf.2016.03.021.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Dahl, Jordi S., and Rasmus Carter-Storch. "First-Phase Ejection Fraction." JACC: Cardiovascular Imaging 12, no. 1 (January 2019): 64–66. http://dx.doi.org/10.1016/j.jcmg.2018.10.007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

VANDECKER, W. "Gated SPECT thallium ejection fraction calculation comparative to calculated echo ejection fraction." Journal of Nuclear Cardiology 4, no. 1 (February 1997): S73. http://dx.doi.org/10.1016/s1071-3581(97)91402-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Petutschnigg, J., and F. Edelmann. "Heart failure with mid-range ejection fraction and with preserved ejection fraction." Herz 43, no. 5 (June 28, 2018): 392–405. http://dx.doi.org/10.1007/s00059-018-4729-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Formiga, F. "Is heart failure with midrange ejection fraction similar to preserved ejection fraction? Against." Revista Clínica Española (English Edition) 217, no. 5 (June 2017): 299–301. http://dx.doi.org/10.1016/j.rceng.2017.01.005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

M, Chandrashekar, and Rangaswamy Rangaswamy. "COMPARATIVE STUDY OF HEART FAILURE WITH PRESERVED EJECTION FRACTION VERSUS DECREASED EJECTION FRACTION." Journal of Evolution of Medical and Dental Sciences 4, no. 24 (March 17, 2015): 3925–32. http://dx.doi.org/10.14260/jemds/2015/566.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Kanagala, Prathap, Jayanth R. Arnold, Adrian S. H. Cheng, Anvesha Singh, Jamal N. Khan, Gaurav S. Gulsin, Jing Yang, et al. "Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction." International Journal of Cardiovascular Imaging 36, no. 1 (August 10, 2019): 101–10. http://dx.doi.org/10.1007/s10554-019-01684-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Soslow, Jonathan H., Emem Usoro, Li Wang, and David A. Parra. "Evaluation of tricuspid annular plane systolic excursion measured with cardiac MRI in children with tetralogy of Fallot." Cardiology in the Young 26, no. 4 (August 17, 2015): 718–24. http://dx.doi.org/10.1017/s1047951115001456.

Full text
Abstract:
AbstractBackgroundAneurysmal dilation of the right ventricular outflow tract complicates assessment of right ventricular function in patients with repaired tetralogy of Fallot. Tricuspid annular plane systolic excursion is commonly used to estimate ejection fraction. We hypothesised that tricuspid annular plane systolic excursion measured by cardiac MRI approximates global and segmental right ventricular function, specifically right ventricular sinus ejection fraction, in children with repaired tetralogy of Fallot.MethodsTricuspid annular plane systolic excursion was measured retrospectively on cardiac MRIs in 54 patients with repaired tetralogy of Fallot. Values were compared with right ventricular global, sinus, and infundibular ejection fractions. Tricuspid annular plane systolic excursion was indexed to body surface area, converted into a fractional value, and converted into published paediatric Z-scores.ResultsTricuspid annular plane systolic excursion measurements had good agreement between observers. Right ventricular ejection fraction did not correlate with the absolute or indexed tricuspid annular plane systolic excursion and correlated weakly with fractional tricuspid annular plane systolic excursion (r=0.41 and p=0.002). Segmental right ventricular function did not appreciably improve correlation with any of the tricuspid annular plane systolic excursion measures. Paediatric Z-scores were unable to differentiate patients with normal and abnormal right ventricular function.ConclusionsTricuspid annular plane systolic excursion measured by cardiac MRI correlates poorly with global and segmental right ventricular ejection fraction in children with repaired tetralogy of Fallot. Tricuspid annular plane systolic excursion is an unreliable approximation of right ventricular function in this patient population.
APA, Harvard, Vancouver, ISO, and other styles
24

Hanna, L., V. Lopez-Majano, J. Ward, M. Mathew, and J. A. Aldrete. "NON-INVASIVE EJECTION FRACTION MONITORING." Anesthesiology 69, no. 3A (September 1, 1988): A308. http://dx.doi.org/10.1097/00000542-198809010-00307.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

MARUSCHAK, GARY F., and JAMES F. SCHAUBLE. "Limitations of thermodilution ejection fraction." Critical Care Medicine 13, no. 8 (August 1985): 679–82. http://dx.doi.org/10.1097/00003246-198508000-00015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Kruskal, J. F., S. N. Nadel, C. E. Spritzer, A. J. Evans, and H. D. Sostman. "MRI-CARDIAC EJECTION FRACTION MEASUREMENT." Investigative Radiology 26, no. 12 (December 1991): 1144. http://dx.doi.org/10.1097/00004424-199112000-00117.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Koorn, R., D. L. Reich, R. Tamman, J. Narang, and Z. Hillel. "RIGHT VENTRICULAR EJECTION FRACTION MEASUREMENT." Anesthesiology 75, no. 3 (September 1, 1991): A386. http://dx.doi.org/10.1097/00000542-199109001-00386.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Spinale, Francis G., James L. Zellner, Rupak Mukherjee, Stephanie E. Ferris, and Fred A. Crawford. "Thermodilution Right Ventricular Ejection Fraction." Chest 98, no. 5 (November 1990): 1259–65. http://dx.doi.org/10.1378/chest.98.5.1259.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Tanasescu, Doina E., and Jay W. Marks. "REPRODUCIBILITY OF GALLBLADDER EJECTION FRACTION." Clinical Nuclear Medicine 11, Supplement (September 1986): P13. http://dx.doi.org/10.1097/00003072-198609001-00016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Sanderson, John E. "Ejection Fraction in Heart Failure." American Journal of Cardiology 105, no. 12 (June 2010): 1844–45. http://dx.doi.org/10.1016/j.amjcard.2010.03.024.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Marwick, Thomas H. "Ejection Fraction Pros and Cons." Journal of the American College of Cardiology 72, no. 19 (November 2018): 2360–79. http://dx.doi.org/10.1016/j.jacc.2018.08.2162.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Richards, Lisa. "Ejection fraction and risk prediction." Nature Reviews Cardiology 6, no. 9 (September 2009): 559. http://dx.doi.org/10.1038/nrcardio.2009.128.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Malloch, C., G. A. Wright, M. McDade, W. Martin, and I. Hutton. "Ejection fraction from gated SPET." Nuclear Medicine Communications 20, no. 5 (May 1999): 458. http://dx.doi.org/10.1097/00006231-199905000-00014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Camafort Babkowski, M. "Is heart failure with midrange ejection fraction similar to preserved ejection fraction? In favor." Revista Clínica Española (English Edition) 217, no. 5 (June 2017): 296–98. http://dx.doi.org/10.1016/j.rceng.2017.01.003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Steahr, Gregg, Linda Kelly, Meredith Moore, and Brenda Hott. "Heart Failure Preserved Ejection Fraction Patients Benefit From Heart Failure Reduced Ejection Fraction Guidelines." Journal of Cardiac Failure 21, no. 8 (August 2015): S73—S74. http://dx.doi.org/10.1016/j.cardfail.2015.06.232.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Aydogan, Mehmet, Sevket Balta, Sait Demirkol, Seyfettin Gumus, Zekeriya Arslan, and Murat Unlu. "Heart failure: Not only reduced left ventricular ejection fraction but also reserved ejection fraction!" Heart & Lung 42, no. 3 (May 2013): 229. http://dx.doi.org/10.1016/j.hrtlng.2013.01.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Di Gioia, Giuseppe, Bernard De Bruyne, Mariano Pellicano, Jozef Bartunek, Iginio Colaiori, Antonella Fiordelisi, Grazia Canciello, et al. "Fractional flow reserve in patients with reduced ejection fraction." European Heart Journal 41, no. 17 (August 16, 2019): 1665–72. http://dx.doi.org/10.1093/eurheartj/ehz571.

Full text
Abstract:
Abstract Aims Fractional flow reserve (FFR) has never been investigated in patients with reduced ejection fraction and associated coronary artery disease (CAD). We evaluated the impact of FFR on the management strategies of these patients and related outcomes. Methods and results From 2002 to 2010, all consecutive patients with left ventricular ejection fraction (LVEF) ≤50% undergoing coronary angiography with ≥1 intermediate coronary stenosis [diameter stenosis (DS)% 50–70%] treated based on angiography (Angiography-guided group) or according to FFR (FFR-guided group) were screened for inclusion. In the FFR-guided group, 433 patients were matched with 866 contemporary patients of the Angiography-guided group. For outcome comparison, 617 control patients with LVEF &gt;50% were included. After FFR, stenotic vessels per patient were significantly downgraded compared with the Angiography-guided group (1.43 ± 0.98 vs. 1.97 ± 0.84; P &lt; 0.001). This was associated with lower revascularization rate (52% vs. 62%; P &lt; 0.001) in the FFR-guided vs. the Angiography-guided group. All-cause death at 5 years of follow-up was significantly lower in the FFR-guided as compared with Angiography-guided group [22% vs. 31%. HR (95% CI) 0.64 (0.51–0.81); P &lt; 0.001]. Similarly, rate of major adverse cardiovascular and cerebrovascular events (MACCE: composite of all-cause death, myocardial infarction, revascularization, and stroke) was significantly lower in the FFR-guided group [40% vs. 46% in the Angiography-guided group. HR (95% CI) 0.81 (0.67–0.97); P = 0.019]. Higher rates of death and MACCE were observed in patients with reduced LVEF compared with the control cohort. Conclusions In patients with reduced LVEF and CAD, FFR-guided revascularization was associated with lower rates of death and MACCE at 5 years as compared with the Angiography-guided strategy. This beneficial impact was observed in parallel with less coronary artery bypass grafting and more patients deferred to percutaneous coronary intervention or medical therapy.
APA, Harvard, Vancouver, ISO, and other styles
38

James, Katherine A., Jane Gralla, Leslie A. Ridall, ThuyQuynh N. Do, Angela S. Czaja, Peter M. Mourani, Emma Ciafaloni, et al. "Left ventricular dysfunction in Duchenne muscular dystrophy." Cardiology in the Young 30, no. 2 (January 22, 2020): 171–76. http://dx.doi.org/10.1017/s1047951119002610.

Full text
Abstract:
AbstractBackground:Duchenne muscular dystrophy is associated with progressive cardiorespiratory failure, including left ventricular dysfunction.Methods and Results:Males with probable or definite diagnosis of Duchenne muscular dystrophy, diagnosed between 1 January, 1982 and 31 December, 2011, were identified from the Muscular Dystrophy Surveillance Tracking and Research Network database. Two non-mutually exclusive groups were created: patients with ≥2 echocardiograms and non-invasive positive pressure ventilation-compliant patients with ≥1 recorded ejection fraction. Quantitative left ventricular dysfunction was defined as an ejection fraction <55%. Qualitative dysfunction was defined as mild, moderate, or severe. Progression of quantitative left ventricular dysfunction was modelled as a continuous time-varying outcome. Change in qualitative left ventricle function was assessed by the percentage of patients within each category at each age. Forty-one percent (n = 403) had ≥2 ejection fractions containing 998 qualitative assessments with a mean age at first echo of 10.8 ± 4.6 years, with an average first ejection fraction of 63.1 ± 12.6%. Mean age at first echo with an ejection fraction <55 was 15.2 ± 3.9 years. Thirty-five percent (140/403) were non-invasive positive pressure ventilation-compliant and had ejection fraction information. The estimated rate of decline in ejection fraction from first ejection fraction was 1.6% per year and initiation of non-invasive positive pressure ventilation did not change this rate.Conclusions:In our cohort, we observed that left ventricle function in patients with Duchenne muscular dystrophy declined over time, independent of non-invasive positive pressure ventilation use. Future studies are needed to examine the impact of respiratory support on cardiac function.
APA, Harvard, Vancouver, ISO, and other styles
39

Nakano, Kathy Jean, Kenneth Waxman, Daniel Rimkus, and John Blaustein. "Does Gallbladder Ejection Fraction Predict Pathology after Elective Cholecystectomy for Symptomatic Cholelithiasis ?" American Surgeon 68, no. 12 (December 2002): 1052–56. http://dx.doi.org/10.1177/000313480206801205.

Full text
Abstract:
Patients with symptomatic cholelithiasis are selected for elective cholecystectomy with the expectation that their symptoms will improve after operation. However, some patients fail to improve because their preoperative symptoms were not related to gallbladder disease. A test that would indicate the severity of gallbladder disease in patients with gallstones would therefore have great potential benefit. Twenty-five patients who presented as outpatients with episodic abdominal pain and gallstones were scheduled for elective cholecystectomy. On the day before operation patients underwent nuclear medicine cholescintigraphy with measurement of ejection fraction. All patients then underwent laparoscopic cholecystectomy. Pathologic specimens were reviewed by a pathologist who was blinded to the ejection fraction results and scored for degree of inflammation on a scale of zero to three. There was a wide range of ejection fractions measured (0–84%). There was, however, no correlation between ejection fractions and degree of gallbladder inflammation. We conclude that gallbladder ejection fraction does not predict the degree of gallbladder inflammation at the time of elective cholecystectomy. This test is therefore unlikely to predict which patients with cholelithiasis will have symptomatic relief after cholecystectomy.
APA, Harvard, Vancouver, ISO, and other styles
40

Kebede, Bekalu, Melese Getachew, Yalew Molla, Bereket Bahiru, and Bekalu Dessie. "Management, survival, and predictors of mortality among hospitalized heart failure patients at Debre Markos comprehensive specialized hospital, Northwest Ethiopia: Prospective cohort study." SAGE Open Medicine 9 (January 2021): 205031212110573. http://dx.doi.org/10.1177/20503121211057336.

Full text
Abstract:
Introduction: Heart failure is a major public health problem worldwide. Since heart failure with reduced ejection fraction and preserved ejection fraction are different clinical entities, in-hospital mortality may occur at different rates. This study aimed to assess the management, survival, and predictors of mortality among hospitalized heart failure patients at Debre Markos comprehensive specialized medical ward. Methods: A prospective cohort study was conducted on 228 heart failure patients at Debre Markos Comprehensive Specialized Hospital medical wards. A structured data collection tool was used to collect data. Data were analyzed using SPSS version 21.0. The Kaplan–Meier survival curve was used to investigate if there was a difference in the in-hospital survival between heart failure with a reduced ejection fraction and heart failure with a preserved ejection fraction. Those variables having p-value < 0.05 were considered statistically significant. Results: From the 228 participants, 126 (55.3%) were females with a mean age of 53.32 ± 15.68 years. One hundred thirty-three (58.3%) patients were presented with preserved (⩾50%) level of ejection fraction. The all-cause in-hospital death rate was 12.7%, and the risk of in-hospital mortality was higher in heart failure patients with reduced ejection fraction (7.4% vs 5.3%; p = 0.005). Current occupation ( p = 0.041), elevated serum creatinine ( p = 0.010), reduced ejection fraction ( p = 0.017), and asthma/chronic obstructive pulmonary disease comorbidity ( p = 0.002) were the independent predictors of high hospital mortality. Conclusion: The rate of in-hospital mortality among heart failure patients was high. Healthcare providers should provide effective education activities and define disease management strategies for patients with reduced ejection fractions.
APA, Harvard, Vancouver, ISO, and other styles
41

Johansson, Isabelle, Ulf Dahlström, Magnus Edner, Per Näsman, Lars Rydén, and Anna Norhammar. "Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function." Diabetes and Vascular Disease Research 15, no. 6 (September 3, 2018): 494–503. http://dx.doi.org/10.1177/1479164118794619.

Full text
Abstract:
Objective: To study the characteristics and prognostic implications of type 2 diabetes in different heart failure entities from a nationwide perspective. Methods: This observational study comprised 30,696 heart failure patients prospectively included in the Swedish Heart Failure Registry (SwedeHF) 2003–2011 from specialist care, with mortality information available until December 2014. Patients were categorized into three heart failure entities by their left ventricular ejection fraction (heart failure with preserved ejection fraction: ⩾50%, heart failure with mid-range ejection fraction: 40%–49% and heart failure with reduced ejection fraction: <40%). All-cause mortality stratified by type 2 diabetes and heart failure entity was studied by Cox regression. Results: Among the patients, 22% had heart failure with preserved ejection fraction, 21% had heart failure with mid-range ejection fraction and 57% had heart failure with reduced ejection fraction. The proportion of type 2 diabetes was similar, ≈25% in each heart failure entity. Patients with type 2 diabetes and heart failure with preserved ejection fraction were older, more often female and burdened with hypertension and renal impairment compared with heart failure with mid-range ejection fraction and heart failure with reduced ejection fraction patients among whom ischaemic heart disease was more common. Type 2 diabetes remained an independent mortality predictor across all heart failure entities after multivariable adjustment, somewhat stronger in heart failure with left ventricular ejection fraction below 50% (hazard ratio, 95% confidence interval; heart failure with preserved ejection fraction: 1.32 [1.22–1.43], heart failure with mid-range ejection fraction: 1.51 [1.39–1.65], heart failure with reduced ejection fraction: 1.46 [1.39–1.54]; p-value for interaction, p = 0.0049). Conclusion: Type 2 diabetes is an independent mortality predictor across all heart failure entities increasing mortality risk by 30%–50%. In type 2 diabetes, the heart failure with mid-range ejection fraction entity resembles heart failure with reduced ejection fraction in clinical characteristics, risk factor pattern and prognosis.
APA, Harvard, Vancouver, ISO, and other styles
42

Chrisnanda, Rima Hayyu, M. Robiul Fuadi, S. P. Edijanto, and M. Yusuf. "Relationship between Serum Dehydroepiandrosterone Levels and Heart Ejection Fraction in Heart Failure Patients." INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY 27, no. 2 (April 15, 2021): 201. http://dx.doi.org/10.24293/ijcpml.v27i2.1664.

Full text
Abstract:
Cardiovascular disease is still a serious problem in the world of health. Life expectancy after being diagnosed with heartfailure is 50% and 10% for 5 and 10 years. Steroid hormones such as Dehydroepiandrosterone (DHEAS) havecardioprotective effects by inhibiting the formation of atherosclerotic plaque, pulmonary artery vasodilators, and protectingcardiomyocytes. DHEAS levels decrease with age. Decreased DHEAS levels are associated with an increased risk ofcardiovascular disease. This study aimed to know the relationship between DHEAS levels in serum and ejection fractions inheart failure patients. This cross-sectional study used a sample of 34 people aged > 30 years who had been diagnosed withheart failure by a specialist in the Department of Cardiology and Vascular Medicine. The diagnosis of heart failure usesEchocardiography to determine the ejection heart fraction. DHEAS levels were taken from venous blood and examinedusing the CLEIA method with an IMMULITE device (Siemens Healthineers, Germany). Statistical analysis was performed bySpearman correlation test, with a significance level of p < 0.05. Thirty-four research subjects found that 13 patients had anejection fraction of 40% (Heart Failure with Reduced Ejection Fraction/HFrEF), 12 patients had an ejection fraction of 41-49%(borderline) and 9 patients had an ejection fraction of ≥ 50% (Heart Failure with Preserved Ejection Fraction/HFpEF).Spearman correlation test results obtained a correlation coefficient or r=0.357 with a value of p=0.038, which meant therewas a significant relationship between DHEAS with ejection fraction (p < 0.05). The lower the DHEAS level, the ejectionfraction would also be lower. Further with age, DHEAS levels get lower. The lower the DHEAS level, the lower the ejectionfraction.
APA, Harvard, Vancouver, ISO, and other styles
43

Bulashova, O. V., A. A. Nasybullina, E. V. Khazova, V. M. Gazizyanova, and V. N. Oslopov. "Heart failure patients with mid-range ejection fraction: clinical features and prognosis." Kazan medical journal 102, no. 3 (June 10, 2021): 293–301. http://dx.doi.org/10.17816/kmj2021-293.

Full text
Abstract:
Aim. To analyze clinical and echocardiographic characteristics and prognosis in patients with heart failure mid-range ejection fraction. Methods. The study included 76 patients with stable heart failure IIV functional class, with a mean age of 66.110.4 years. All patients were divided into 3 subgroups based on the left ventricular ejection fraction: the first group heart failure patients with reduced ejection fraction (below 40%), 21.1%; the second group patients with mid-range ejection fraction (from 40 to 49%), 23.7%; the third group patients with preserved ejection fraction (50%), 55.3%. The clinical characteristics of all groups were compared. The quality of life was assessed by the Minnesota Satisfaction Questionnaire (MSQ), the clinical condition was determined by using the clinical condition assessment scale (Russian Shocks). The prognosis was studied according to the onset of cardiovascular events one year after enrollment in the study. The endpoints were cardiovascular mortality, myocardial infarction (MI), stroke, hospitalization for acutely decompensated heart failure, thrombotic complications. Statistical analysis was performed by using IBM SPSS Statistics 20 software. Normal distribution of the data was determined by the ShapiroWilk test, nominal indicators were compared between groups by using chi-square tests, normally distributed quantitative indicators by ANOVA. The KruskalWallis test was performed to comparing data with non-normal distribution. Results. Analysis showed that the most of clinical characteristics (etiological structure, age, gender, quality of life, results on the clinical condition assessment scale for patients with chronic heart failure and a 6-minute walk test, distribution by functional classes of heart failure) in patients with mid-range ejection fraction (HFmrEF) were similar to those in patients with reduced ejection fraction (HFrEF). At the same time, they significantly differed from the characteristics of patients with preserved ejection fraction (HFpEF). Echocardiographic data from patients with mid-range ejection fraction ranks in the middle compared to patients with reduced and preserved ejection fraction. In heart failure patients with mid-range ejection fraction, the incidence of adverse outcomes during the 1st year also was intermediate between heart failure patients with preserved ejection fraction and patients with reduced ejection fraction: for all cardiovascular events in the absence of significant differences (17.6; 10.8 and 18.8%, respectively), myocardial infarction (5,9; 0 and 6.2%), thrombotic complications (5.9; 5.4 and 6.2%). Heart failure patients with mid-range ejection fraction in comparison to patients with preserved ejection fraction and reduced ejection fraction had significantly lower cardiovascular mortality (0; 2.7 and 12.5%, p 0.05) and the number of hospitalization for acutely decompensated heart failure (0; 2,7 and 6.2%). Conclusion. Clinical characteristics of heart failure patients with mid-range and heart failure patients with reduced ejection fraction are similar but significantly different from those in the group of patients with preserved ejection fraction; echocardiographic data in heart failure patients with mid-range ejection fraction is intermediate between those in patients with reduced ejection fraction and patients with preserved ejection fraction; the prognosis for all cardiovascular events did not differ significantly in the groups depending on the left ventricular ejection fraction.
APA, Harvard, Vancouver, ISO, and other styles
44

Ibrahim, Walid, AhmedS Yassin, Ahmed Subahi, Hassan Mohamed, Ayman Khaddam, Muhammad Bajwa, Ashraf Abugroun, Amir Kaki, Mahir Elder, and Tamam Mohamad. "Sacubitril/valsartan improves ejection fraction in heart failure with reduced ejection fraction: A retrospective study." Clinical Trials in Degenerative Diseases 3, no. 4 (2018): 119. http://dx.doi.org/10.4103/2542-3975.248010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Kato, Masahiko, and Kazuhiro Yamamoto. "Monitoring Changes in Ejection Fraction in Patients With Heart Failure and Mid-Range Ejection Fraction." Circulation Journal 82, no. 8 (July 25, 2018): 1991–93. http://dx.doi.org/10.1253/circj.cj-18-0663.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Allouche, Emna, Habib Ben Ahmed, Wejdène Ouechtati, Mariem Jabeur, Slim Sidhom, Sami Marouen, Leila Bezdah, and Hédi Baccar. "0156: Heart failure in the elderly: comparison between reduced ejection fraction and preserved ejection fraction." Archives of Cardiovascular Diseases Supplements 6 (April 2014): 19. http://dx.doi.org/10.1016/s1878-6480(14)71315-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Satomura, Hajime, Hiroshi Wada, Kenichi Sakakura, Norifumi Kubo, Nahoko Ikeda, Yoshitaka Sugawara, Junya Ako, and Shin-ichi Momomura. "Congestive heart failure in the elderly: Comparison between reduced ejection fraction and preserved ejection fraction." Journal of Cardiology 59, no. 2 (March 2012): 215–19. http://dx.doi.org/10.1016/j.jjcc.2011.11.014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Dunlay, Shannon M., Véronique L. Roger, Susan A. Weston, Ruoxiang Jiang, and Margaret M. Redfield. "Longitudinal Changes in Ejection Fraction in Heart Failure Patients With Preserved and Reduced Ejection Fraction." Circulation: Heart Failure 5, no. 6 (November 2012): 720–26. http://dx.doi.org/10.1161/circheartfailure.111.966366.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Cao, Thong Huy. "Left Ventricular Ejection Fraction Cut Point of 50% for Heart Failure With Preserved Ejection Fraction." JAMA Cardiology 3, no. 10 (October 1, 2018): 1023. http://dx.doi.org/10.1001/jamacardio.2018.1906.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Bajaj, Navkaranbir S., Brian Claggett, Eldrin F. Lewis, Akshay S. Desai, James C. Fang, Eileen O'Meara, Sanjiv J. Shah, et al. "Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction." European Journal of Heart Failure 20, no. 4 (October 25, 2017): 815–16. http://dx.doi.org/10.1002/ejhf.1040.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Ejection fraction' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography